<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331834</url>
  </required_header>
  <id_info>
    <org_study_id>PrEP_COVID</org_study_id>
    <nct_id>NCT04331834</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic</brief_title>
  <acronym>PrEP_COVID</acronym>
  <official_title>Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorios Rubió</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Plató</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Granollers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barcelona Institute for Global Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with
      hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The study has been suspended until a new epidemic curve occurs.
  </why_stopped>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed cases of a COVID-19</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>Confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 on day 0 and negative serology for SARS-CoV-2 on day 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 seroconversion</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>SARS-CoV-2 seroconversion in the PrEP group compared to placebo in during 6 months of follow-up in healthcare workers with negative serology at day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any adverse event related with hydroxychloroquine treatment</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>Incidence of clinical and/or laboratory adverse events will be compared in the PrEP group and in the placebo arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers will be estimated by the number of healthcare workers diagnosed with COVID-19 in the placebo group, among the total of healthcare workers included in the non-PrEP group during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 Biobank</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>A repository (biobank) of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Pre-exposure prophylaxis of SARS-CoV-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months</description>
    <arm_group_label>Pre-exposure prophylaxis of SARS-CoV-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months</description>
    <arm_group_label>Control group with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Negative PCR and negative serology on day 0

          -  Healthcare worker at any of the trial sites

          -  Female participants: negative for pregnancy test

          -  Willing to participate in the study

          -  Able to sign the informed consent form

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy or breastfeeding

          -  Ongoing antiviral or antiretroviral treatment or HIV positive

          -  Ongoing anti-inflammatory treatment (corticosteroids)

          -  Ongoing or previous (1 month) chloroquine or hydroxychloroquine treatment

          -  Confirmed case of SARS-CoV-2 infection (positive PCR) at day 0

          -  Positive serology for SARS-CoV-1 infection at day 0

          -  Impossibility of signing the informed consent form

          -  Rejection of participation

          -  Working less than 3 days a week in the Hospital Clinic of Barcelona.

          -  Any contraindication for hydroxychloroquine treatment:

               -  Hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity

               -  Retinopathy, visual field or visual acuity disturbances

               -  QT prolongation, bradycardia (&lt;50bpm), ventricular tachycardia, other
                  arrhythmias, as determined on day 0 ECG or medical history

               -  Potassium &lt; 3 mEq/L or AST or ALT &gt; 5 upper normal limit, as determined on day 0
                  blood test

               -  Previous myocardial infarction

               -  Myasthenia gravis

               -  Porphyria

               -  Glomerular clearance &lt; 10ml/min

               -  Previous history of severe hypoglycaemia

               -  Ongoing treatment with antimalarials, antiarrhythmic, tricyclic antidepressants,
                  selective serotonin reuptake inhibitors, natalizumab, quinolones, macrolides,
                  agalsidase alfa and beta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Muñoz Gutiérrez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Institute for Global Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISGlobal</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>pre-exposure</keyword>
  <keyword>healthcare workers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

